Experimental drug aims to tame severe asthma and COPD attacks
Disease control
Not yet recruiting
This trial tests a single dose of rademikibart, given intravenously, as an add-on treatment for people hospitalized with an acute asthma or COPD flare-up who also have type 2 inflammation. The study includes 40 adults and measures how well the drug improves lung function and cont…
Phase: PHASE2 • Sponsor: Connect Biopharm LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC